Media ReleasesImmutep

View All Immutep News


Immutep announces publication of SITC 2021 abstracts


• Data from Phase IIb AIPAC, including final Overall Survival data, reported in a separate announcement
• Encouraging Objective Response Rate (ORR) of 29.7% (11/37), including 5 Complete Responses in 2nd line head and neck squamous cell carcinoma (HNSCC) patients in Part C of Phase II TACTI-002 trial
• TACTI-002 trial (Part C) shows encouraging antitumor activity
• Total of 154 1st line HNSCC patients, unselected for PD-L1 expression, will be recruited into Phase II TACTI-003 study to determine ORR as primary endpoint
• Global Investor Webcast to be held at 8 am on 17 November 2021 (Sydney time) - details below

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that data from its AIPAC, TACTI 002 and TACTI-003 studies have been published in abstracts available via the links below on the SITC 2021 Annual Meeting’s official website or the Company’s website.

Three poster presentations with additional data and commentary that are not included in the abstracts will be available on https://www.sitcancer.org/2021/home from 12 November 2021, at 7 am EST and made available on Immutep’s website at www.immutep.com.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.